The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients.
Ferrandina, M. G., Corrado, G., Mascilini, F., Malaguti, P., Samaritani, R., Distefano, M. G., Masciullo, V., Di Legge, A., Savarese, A., Scambia, G., Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study, <<BMC CANCER>>, 2014; 14 (Dicembre): 947-947. [doi:10.1186/1471-2407-14-947] [http://hdl.handle.net/10807/67109]
Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
Ferrandina, Maria Gabriella;Corrado, Giacomo;Mascilini, Floriana;Malaguti, Paola;Distefano, Maria Grazia;Masciullo, Valeria;Scambia, Giovanni
2014
Abstract
The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2. MOC.pdf
accesso aperto
Descrizione: Articolo principale
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
324.91 kB
Formato
Adobe PDF
|
324.91 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
